This open‐label, single‐arm, phase II trial evaluated the efficacy and immune cell profile of the modified regimen combining atezolizumab, bevacizumab (7.5 mg/kg) and chemotherapy in patients with EGFR‐mutated NSCLC following TKI failure. This evidence concerns the gene EGFR and non-small cell lung carcinoma.